Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.81 |
| ▸ | MEN1 | O00255 | 11/20 | 0.81 |
| ▸ | MAPT | P10636 | 10/20 | 0.81 |
| ▸ | RAB9A | P51151 | 10/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 9/20 | 0.81 |
| ▸ | NPC1 | O15118 | 9/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.81 |
| ▸ | RELA | Q04206 | 6/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.81 |
| ▸ | CASP3 | P42574 | 4/20 | 0.81 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.81 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.81 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 6/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7998301 | 0.91 | MAPT (0.81) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL403442 | 0.89 | KMT2A (0.66) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL7995544 | 0.85 | ALOX15 (0.80) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL10357444 | 0.85 | MEN1 (0.80) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL22415561 | 0.83 | MAPT (0.66) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL10358565 | 0.82 | RAB9A (0.77) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL17943327 | 0.80 | ALOX15 (0.65) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL10357451 | 0.79 | ALOX15 (0.58) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL15425113 | 0.78 | MAPT (0.62) | KMT2AMEN1MAPTRAB9AALOX15 | |
| SCHEMBL15425090 | 0.78 | ALOX15 (0.64) | KMT2AMEN1MAPTRAB9AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307381-B1 | NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| EP-2687513-A1 | Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases | Ludwig-Maximilians-Universität München (DE) | 2014-01-22 | — | — | EP | disclosed |
| EP-2684873-A1 | DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | Ludwig-Maximilians-Universität München (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. | 2011-12-01 | — | — | US | disclosed |
| WO-2010111653-A2 | MODULATING IRES-MEDIATED TRANSLATION | THE UAB RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010000372-A2 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185730-A1 | DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, APP, HYPK | KMT2A 4175/4885MEN1 1938/4885MAPT 8/4885 |
| US-20120184583-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KMT2A 4334/4885MEN1 4723/4885MAPT 4385/4885 |
| US-20100144798-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KMT2A 4334/4885MEN1 4723/4885MAPT 4385/4885 |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | EIF2AK2, EIF4EBP1, EIF4E | KMT2A 2702/4885MEN1 3203/4885MAPT 4312/4885 |
| US-20110293520-A1 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES | PARK7, HYPK, IK | KMT2A 4170/4885MEN1 2126/4885MAPT 40/4885 |
| US-10435373-B2 | Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases | PARK7, APP, HYPK | KMT2A 4175/4885MEN1 1938/4885MAPT 8/4885 |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | EIF2AK2, RPS25, RPL35 | KMT2A 3780/4885MEN1 3891/4885MAPT 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.